Table 4: Treatment emergent adverse events: Zembrin versus placebo.

CategorySigns/symptomsMinimal = 1Mild = 2Moderate = 3Severe = 4
ZPZPZPZP

HeadHeadache0000050
EyesEye irritation00000005
EyesVision blurred00500005
EarsPoor hearing55000000
MouthHypersalivation05000000
MouthDental problems00005500
ChestChest pain00500000
ChestCoughing05000000
GastrointestinalGI discomfort0005009.50
GINausea00005000
GIVomiting00005000
GIConstipation00000050
GIFlatulence00050050
GIAppetite increase50005000
GIAppetite decrease050100500
GIWeight gain140000000
GIWeight loss5100150000
GIThirst increase00505000
GUIncreased frequency00050500
GUGenital discomfort00005000
GUIncreased libido00000500
MusculoskeletalMuscle/bone/joint pain500501005
MSRigidity (muscle)00005000
SkinSkin irritation0001001000
SkinHair problems05050500
Psychiatric: PSTiredness/fatigue00500050
PSOverarousal05000500
PSDifficulty falling asleep000100000
PSEarly morning awakenings55050000
PSInterrupted sleep000100000
PSDrowsiness00000050
PSConfusion00005000
PSConcentration difficulty00000050
PSMemory problems05005000
PSDepression00005000
PSAnxiety05005000
PSIrritability00050000

NB: no life-threatening adverse events were found.
Frequency of adverse events ≥5%. Z: Zembrin treated group. P: placebo treated group.